DOCSLIB.ORG

Planning and Implementing a Swiss Radio-Oncology Network

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Planning and Implementing a Swiss Radio-Oncology Network Chair Secretary PROTON Michael Goitein Ph. D. Daniel Miller Ph. D. THERAPY Department of Radiation Oncology Department of Radiation Medicine C O- Massachusetts General Hospital Loma Linda University Medical Center OPERATIVE Boston MA 02114 Loma Linda CA 92354 G ROUP (617) 724 - 9529 (909) 824 - 4197 (617) 724 - 9532 Fax (909) 824 - 4083 Fax ABSTRACTS of the XXIV PTCOG MEETING held in Detroit, Michigan, USA April 24-26 1996 1 INDEX Page PTCOG Focus Session I: Comparative treatment planning of nasopharyngeal tumors PTCOG nasopharynx treatment planning intercomparison. 5 A. Smith PTCOG Focus Session II: Proton theray clinical studies Proton therapy in 1996: a world wide perspective. 6 J. M. Sisterson Arteriovenous malformations: the NAC experience. 6 F. Vernimmen, J. Wilson, D. Jones, N. Schreuder, E. De Kock, J. Symons Preliminary results of carbon-ion therapy at NIRS. 6 H. Tsujii, J. Mizoe, T. Miyamoto, S. Morita, M. Mukai, T. Nakano, H. Kato, T. Kamada, K. Morita Proton radiation therapy for orbital and parameningeal rhabdomyosarcoma. 7 E. B. Hug, J.A. Adams, J. E. Munzenrider Conformal radiation therapy for retinoblastoma: comparison of various 3D proton plans. 8 M. Krengli, J. A Adams, E. B Hug PTCOG Focus Session III Radiotherapy in the treatment of prostate cancer: neutrons, protons or photons? An analysis of acute and late toxicity in a randomized study of pion vs. photon irradiation 9 for stage T3/4 prostate cancer. T. Pickles, G. Goodman, M. Dimitrov, G. Duncan, C. Fryer, P. Graham, M. McKenzie, J. Morris, D. Rheaume, I. Syndikus With conformal photon irradiation, who needs particles? 10 J. D. Forman Update of Loma Linda experience with conformal proton treatment of prostate cancer. 11 C. Rossi et al. Actuarial control of PSA in patients irradiated with fast neutrons for prostate carcinoma. 11 F. Richard, M. Octave-Prignot, P. J. Van Cangh, P. Scalliet The effect of local/regional tumor recurrence on survival for patients with carcinomas 12 of the prostate: results from NTCWG protocol #8523. T. W. Griffin and T. F. Pajak Evaluating the therapeutic gain of conformal mixed photon/neutron irradiation 13 in localized and locally advanced adenocarcinoma of the prostate. J. D. Forman, P. Kocheril, P. Chuba, S. Reddy, J. Ruby, T. Alpinheim, C. Orton Poster Session Sensitization of brain tumor cells to fractionated fast neutron irradiation. 14 E. R. Blazek, C. Carpenter, W. Chen, A. J. Lennox, B. Pientak, and T. Kroc D-T neutrons for therapy - Detroit re-visited. 15 L. Cranberg 1 Page In-vivo dosimetry in neutrontherapy utilizing 7LiF dosimeters: preliminary results. 16 J.-M. Denis, Th. Loncol, N. de Patoul, S. Vynckier, P. Scalliet Determination of the absorbed dose from the flux measurements: 17 potentialities of the Faraday cup and activation methods. V. Kostjuchenko, D. Nichiporov, and E. Grusell Microdosimetric investigations in the fast neutron therapy beam at Fermilab:work in progress. 18 K. Langen, A. J. Lennox and P. M. DeLuca A multi-institutional interactive network for intracranial arteriovenous malformations: 18 design implementation and initial experience. R. P. Levy , R. W. M. Schulte, G. K. Steinberg, K. A. Frankel, D. W. Miller, M. P. Marks, J. D. Slater B. Lane, L. Heilbronn, J. M. Slater Iterative target delineation for stereotactic irradiation of AVMs using angiography, CT and MRI. 20 R. P. Levy, R. W. M. Schulte, K. A. Frankel, G. K. Steinberg, M. P. Marks On-line PET imaging of radiotherapy beams. 20 D. W. Litzenberg, F. D. Becchetti, D. A. Roberts, R. Ronningen, A. M. Vander Molen, J. A. Brown, R. K. Ten Haken Radioprotection shielding measurements for 200 MeV protons. 21 A. Mazal, K. Gall, S. Michaud, C. Nauraye, S. Delacroix, J. F. Botolier and M. Louis The project of proton treatment facility at the National Cancer Center Hospital East, Kashiwa. 21 T. Ogino, N. Moriyama, S. Yoshida, S. Ebihara Stereotactic neutron radiosurgery system. 22 S. Song, Z. Lu, X. Zheng PTCOG Focus Session IV: Monte Carlo methods for neutron and proton radiation therapy. Monte Carlo calculations as shielding design tools for heavy charged particle accelerators. 23 S. Agosteo, A. Fassr, A. Ferrari, P.R. Sala, M. Silari, P. Tabarelli Nuclear data for Monte Carlo calculations in neutron and proton therapy 23 and description of a new ICRU report committee. M. B. Chadwick Monte Carlo calculations in neutron therapy. 24 A. Ross Modeling of proton treatment nozzles with the LAHET Monte Carlo code. 24 J. V. Siebers and M. M. Traynor Characterization of particle therapy radiation sources for use with PEREGRINE, 25 the all particle Monte Carlo dose calculation code. L. J. Cox, C. L. Hartmann Siantar, A. E. Schach von Wittenau, J. V. Siebers, M. Traynor Reports from particle therapy facilities PROTOX - a proposal to develop high energy proton beam radiotherapy in Oxford, U.K. 26 D. J. Cole, H. Weatherburn, G. Walker and P. Williams 2 Page Construction of the NPTC Equipment - Status Report and Recent Results. 26 S. Laycock and Y. Jongen Status of the TERA project. 27 M. Krengli The proton therapy partnership in the centre of Italy. 28 R. Santoni, M. Bucciolini, N. Taccetti and G. Biti Progress report on HIMAC Facility. 29 K. Kawachi, Y. Sato, S. Yamada, T. Kanai, M. Endo, E. Takada, T. Murakami, A. Kitagawa, M. Kumada, M. Kanazawa, K. Noda, M. Torikoshi, S. Minohara, N. Miyahara, N. Matsufuji, H. I. Koyama, H. Tomura, Y. Futami, J. Yoshizawa, S. Kohda, H. Ogawa, A. Itano, A. Higashi, N. Araki Proton therapy in Moscow: the state-of-the-art. 30 N. N. Alexeev, S. I. Blokhin, V. M. Breev, V. S. Khoroshkov, E. I. Minakova The hadron radiotherapy centre in Krakow - a project based on 20 years 30 of clinical experience with fast neutrons. M. P. R. Waligorski, P. Olko, J. F. Skolyszewski, A. Budzanowski Physics and technical aspects of proton therapy and new techniques Intercomparisons of proton clinical beams in Russia in light of the Loma Linda intercomparisons. 31 D. Nichiporov, V. Kostjuchenko, A. Molokanov, J. Karlin, S. Vatnitsky Comparative treatment planning: age related maculopathy. 32 A. Mazal, L. Schwarz, F. Lacroix, H. Mammar, S. Delacroix, L. Desjardins, J. L. Habrand A water calorimeter for high-energy protons. 32 H. J. Brede, J. Heese, O. Hecker, R. Hollnagel, H. Kluge, M. Morgenstern Summary of the ICRU proton dosimetry report. 32 L. J. Verhey and D. W. Miller Planning and implementing a Swiss radio-oncology network. 33 A. Lomax, O. Ratib, R. Miralbell, T. Boehringer, L. Cozzi, P.-A. Tercier Positron beam therapy. 34 F. Becchetti, D. Litzenberg, M. Skalsey, R. Ten Haken Robotic approaches for patient positioning systems. 35 A. Mazal, R. Ferrand, J. C. Rosenwald, J. L. Habrand and F. Lafortune Study of a small proton beam field. 35 Y. Takada BNCT and radiobiology A BNCT facility based on an ESQ-accelerator. 36 B. Ludewigt, W. T. Chu, and R. Donahue A novel 2.5 MeV D-D neutron source. 36 G. H. Miley 3 Page Simultaneous Macro and Micro dosimetry for Boron Neutron Capture Therapy with a MOSFET probe. 37 A. B. Rosenfeld, G. I. Kaplan, M. G. Carolan, B. J. Allen, C. Kota, M. Yudelev, R. L. Maughan, J. N. Mathur BOPP: Cytotoxicity, pharmacokinetics and intracellular localization in a human glioma cell line. 39 D. Deen, J. Afzal, E. Blakely, A. Bollen, D. Callahan, W. Chu, L. Hu, S. Kahl, T. L. Phillips RBE data needed for designing clinical trials with new radiation therapy beams. 40 J. Gueulette, V. Gregoire, S. Vynckier, A. Wambersie and P. Scalliet Use of MOSFET gamma dosimeters and silicon P-I-N diode neutron dosimeters 40 for epithermal neutron beam mixed field dosimetry. M. G. Carolan, B. J. Allen, A. B. Rosenfeld, J. N. Mathur Biological effectiveness of absorbed dose in BNCT and BNCEFNT. 41 C. Kota and R. L. Maughan 3D treatment planning for 14 MeV neutrons. 42 R. Schmidt, T. Frenzel, A. Krull, L. Ludemann, T. Matzen Neutron therapy clinical studies Musculoskeletal toxicity of neutron-photon therapy for prostate cancer. 43 P. J. Chuba, R. Soulin, J. Romero, P. Kocheril, M. Yudelev, R. Sharma, R. Maughan, J. D. Forman Neutron therapy for glomus tumours, a possible new indication. 43 F. Vernimmen The lack of benefit of neo-adjuvant hormonal therapy when given in conjunction 44 with mixed neutron-photon irradiation for non-metastatic prostate cancer. P. G. Kocheril, F. Shamsa, J. D. Forman Acute and late reactions of fast neutron therapy in patients with head and neck cancer - the Krakow experience. 45 B. Sas-Korczynska and J. Skolyszewski Neutron radiotherapy for salivary gland tumors at Harper Hospital. 45 E. Ben-Josef, S. Devi, J. Fontanesi, A. Aref Physics and Technical aspects of neutron therapy Biophysical aspects for fast neutron therapy planning. 46 K. H. Hover, P. Pihet, T. Loncol, S. Gerdung A multiblade trimmer for neutron therapy. 46 D. T. L. Jones, A. N. Schreuder, J. E. Symons, P. J. Binns, H. A. Smit, A. Mueller New LiF:Mg,Ti thermoluminescent detectors for hadron radiotherapy. 47 P. Olko, P. Bilski, M. Budzanowski, M. P. R. Waligorski A spectrum integrated convolution model for therapeutic fast neutron beams. 48 M. F. Moyers, J. L. Horton, A. L. Boyer, L. T. Myers Implementation of quality assurance program for Harper Hospital fast neutron therapy unit. 48 M. Yudelev, R. L. Maughan, K. McEnhill, E. Blosser 4 PTCOG nasopharynx treatment planning intercomparison A. Smith, Massachusetts General Hospital; A. Lomax, Paul Scherrer Institute; D. Miller, Loma Linda University Medical Center The Treatment Planning Working Group has continued to develop and implement the tools necessary to carry out treatment planning intercomparisons. We will perform studies for a number of disease sites and will continue to expand the number of participants so that the study will include a complete representation of proton beam delivery and treatment planning methods as well as challenging treatment plans using photons.
Load more

Recommended publications
  • Understanding the Potentiality of Accelerator
    Bortolussi et al. Radiation Oncology (2017) 12:130 DOI 10.1186/s13014-017-0860-6 RESEARCH Open Access Understanding the potentiality of accelerator based-boron neutron capture therapy for osteosarcoma: dosimetry assessment based on the reported clinical experience Silva Bortolussi1,2* , Ian Postuma2, Nicoletta Protti2, Lucas Provenzano3,4, Cinzia Ferrari5,2, Laura Cansolino5,6, Paolo Dionigi5,6, Olimpio Galasso7, Giorgio Gasparini7, Saverio Altieri1,2, Shin-Ichi Miyatake8 and Sara J. González3,4 Abstract Background: Osteosarcoma is the most frequent primary malignant bone tumour, and its incidence is higher in children and adolescents, for whom it represents more than 10% of solid cancers. Despite the introduction of adjuvant and neo-adjuvant chemotherapy that markedly increased the success rate in the treatment, aggressive surgery is still needed and a considerable percentage of patients do not survive due to recurrences or early metastases. Boron Neutron Capture Therapy (BNCT), an experimental radiotherapy, was investigated as a treatment that could allow a less aggressive surgery by killing infiltrated tumour cells in the surrounding healthy tissues. BNCT requires an intense neutron beam to ensure irradiation times of the order of 1 h. In Italy, a Radio Frequency Quadrupole (RFQ) proton accelerator has been designed and constructed for BNCT, and a suitable neutron spectrum was tailored by means of Monte Carlo calculations. This paper explores the feasibility of BNCT to treat osteosarcoma using this neutron source based on accelerator. Methods: The therapeutic efficacy of BNCT was analysed evaluating the dose distribution obtained in a clinical case of femur osteosarcoma. Mixed field dosimetry was assessed with two different formalisms whose parameters were specifically derived from radiobiological experiments involving in vitro UMR-106 osteosarcoma cell survival assays and boron concentration assessments in an animal model of osteosarcoma.
    [Show full text]
  • Targeted Radiotherapeutics from 'Bench-To-Bedside'
    RadiochemistRy in switzeRland CHIMIA 2020, 74, No. 12 939 doi:10.2533/chimia.2020.939 Chimia 74 (2020) 939–945 © C. Müller, M. Béhé, S. Geistlich, N. P. van der Meulen, R. Schibli Targeted Radiotherapeutics from ‘Bench-to-Bedside’ Cristina Müllera, Martin Béhéa, Susanne Geistlicha, Nicholas P. van der Meulenab, and Roger Schibli*ac Abstract: The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for success- ful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affin- ity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties that suit the properties of the targeting molecule and the clinical purpose. The Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute in Switzerland is privileged to be situated close to unique infrastruc- ture for radionuclide production (high energy accelerators and a neutron source) and access to C/B-type labora- tories including preclinical, nuclear imaging equipment and Swissmedic-certified laboratories for the preparation of drug samples for human use. These favorable circumstances allow production of non-standard radionuclides, exploring their biochemical and pharmacological features and effects for tumor therapy and diagnosis, while investigating and characterizing new targeting structures and optimizing these aspects for translational research on radiopharmaceuticals. In close collaboration with various clinical partners in Switzerland, the most promising candidates are translated to clinics for ‘first-in-human’ studies.
    [Show full text]
  • Particle Accelerators and Detectors for Medical Diagnostics and Therapy Arxiv:1601.06820V1 [Physics.Med-Ph] 25 Jan 2016
    Particle Accelerators and Detectors for medical Diagnostics and Therapy Habilitationsschrift zur Erlangung der Venia docendi an der Philosophisch-naturwissenschaftlichen Fakult¨at der Universit¨atBern arXiv:1601.06820v1 [physics.med-ph] 25 Jan 2016 vorgelegt von Dr. Saverio Braccini Laboratorium f¨urHochenenergiephysik L'aspetto pi`uentusiasmante della scienza `eche essa incoraggia l'uomo a insistere nei suoi sogni. Guglielmo Marconi Preface This Habilitation is based on selected publications, which represent my major sci- entific contributions as an experimental physicist to the field of particle accelerators and detectors applied to medical diagnostics and therapy. They are reprinted in Part II of this work to be considered for the Habilitation and they cover original achievements and relevant aspects for the present and future of medical applications of particle physics. The text reported in Part I is aimed at putting my scientific work into its con- text and perspective, to comment on recent developments and, in particular, on my contributions to the advances in accelerators and detectors for cancer hadrontherapy and for the production of radioisotopes. Dr. Saverio Braccini Bern, 25.4.2013 i ii Contents Introduction 1 I 5 1 Particle Accelerators and Detectors applied to Medicine 7 2 Particle Accelerators for medical Diagnostics and Therapy 23 2.1 Linacs and Cyclinacs for Hadrontherapy . 23 2.2 The new Bern Cyclotron Laboratory and its Research Beam Line . 39 3 Particle Detectors for medical Applications of Ion Beams 49 3.1 Segmented Ionization Chambers for Beam Monitoring in Hadrontherapy 49 3.2 Proton Radiography with nuclear Emulsion Films . 62 3.3 A Beam Monitor Detector based on doped Silica Fibres .
    [Show full text]
  • Nuclear Data for Medical Applications ° ° INM-5: Nuklearchemie,INM-5: Forschungszentrum Germjülich, Abteilung Nuklearchemie, Zu Germanuniversitätköln, ° Syed M
    Mitglied der Helmholtz-Gemeinschaft derMitglied Nuclear Data for Medical Applications ° Syed M. Qaim ° INM-5: Nuklearchemie, Forschungszentrum Jülich, Germany; ° Abteilung Nuklearchemie, Universität zu Köln, Germany Plenary Lecture given at a Workshop in the 7 th Framework Programme of the European Union on “Solving Challenges in Nuclear Data for the Safety of Nuclear Facilities (CHANDA)”, Paul Scherrer Institute, Villigen, Switzerland, 23 to 25 November 2015 Outline ° Introduction - external radiation therapy - internal radionuclide applications ° Commonly used radionuclides - status of nuclear data - alternative routes for production of 99m Tc - standardisation of production data ° Research oriented radionuclides - non-standard positron emitters - novel therapeutic radionuclides ° New directions in radionuclide applications ° Future data needs ° Summary and conclusions Nuclear Data Research for Medical Use Aim ° Provide fundamental database for - external radiation therapy - internal radionuclide applications Areas of Work ° Experimental measurements ° Nuclear model calculations ° Standardisation and evaluation of existing data Considerable effort is invested worldwide in nuclear data research External Radiation Therapy • Biological changes under the impact of radiation • Of significance is linear energy transfer (LET) to tissue Types of Therapy • Photon therapy : use of 60 Co or linear accelerator (low-LET radiation ) most common • Fast neutron therapy : accelerator with E p or E d above 50 MeV (high-LET radiation ) being abandoned
    [Show full text]
  • Protocol for Heavy Charged-Particle Therapy Beam Dosimetry
    AAPM REPORT NO. 16 PROTOCOL FOR HEAVY CHARGED-PARTICLE THERAPY BEAM DOSIMETRY Published by the American Institute of Physics for the American Association of Physicists in Medicine AAPM REPORT NO. 16 PROTOCOL FOR HEAVY CHARGED-PARTICLE THERAPY BEAM DOSIMETRY A REPORT OF TASK GROUP 20 RADIATION THERAPY COMMITTEE AMERICAN ASSOCIATION OF PHYSICISTS IN MEDICINE John T. Lyman, Lawrence Berkeley Laboratory, Chairman Miguel Awschalom, Fermi National Accelerator Laboratory Peter Berardo, Lockheed Software Technology Center, Austin TX Hans Bicchsel, 1211 22nd Avenue E., Capitol Hill, Seattle WA George T. Y. Chen, University of Chicago/Michael Reese Hospital John Dicello, Clarkson University Peter Fessenden, Stanford University Michael Goitein, Massachusetts General Hospital Gabrial Lam, TRlUMF, Vancouver, British Columbia Joseph C. McDonald, Battelle Northwest Laboratories Alfred Ft. Smith, University of Pennsylvania Randall Ten Haken, University of Michigan Hospital Lynn Verhey, Massachusetts General Hospital Sandra Zink, National Cancer Institute April 1986 Published for the American Association of Physicists in Medicine by the American Institute of Physics Further copies of this report may be obtained from Executive Secretary American Association of Physicists in Medicine 335 E. 45 Street New York. NY 10017 Library of Congress Catalog Card Number: 86-71345 International Standard Book Number: 0-88318-500-8 International Standard Serial Number: 0271-7344 Copyright © 1986 by the American Association of Physicists in Medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Published by the American Institute of Physics, Inc., 335 East 45 Street, New York, New York 10017 Printed in the United States of America Contents 1 Introduction 1 2 Heavy Charged-Particle Beams 3 2.1 ParticleTypes .........................
    [Show full text]
  • Carbon Ion Therapy for Advanced Sinonasal Malignancies: Feasibility
    Jensen et al. Radiation Oncology 2011, 6:30 http://www.ro-journal.com/content/6/1/30 RESEARCH Open Access Carbon ion therapy for advanced sinonasal malignancies: feasibility and acute toxicity Alexandra D Jensen1*, Anna V Nikoghosyan1, Swantje Ecker2, Malte Ellerbrock2, Jürgen Debus1 and Marc W Münter1 Abstract Purpose: To evaluate feasibility and toxicity of carbon ion therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalation which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon ion therapy offers the advantage of sharp dose gradients promising increased dose application without increase of side-effects. Methods: Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Results: Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiation. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactions; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alterations of taste, all symptoms had resolved at 8 weeks post RT.
    [Show full text]
  • Present Status of Fast Neutron Therapy Survey of the Clinical Data and of the Clinical Research Programmes
    PRESENT STATUS OF FAST NEUTRON THERAPY SURVEY OF THE CLINICAL DATA AND OF THE CLINICAL RESEARCH PROGRAMMES Andre Wambersie and Francoise Richard Universite Catholique de Louvain, Unite de Radiotherapie, Neutron- et CurietheVapie, Cliniques Universitaires St-Luc, 1200-Brussels, Belgium. Abstract The clinical results reported from the different neutron therapy centres, in USA, Europe and Asia, are reviewed. Fast neutrons were proven to be superior to photons for locally extended inoperable salivary gland tumours. The reported overall local control rates are 67 % and 24 % respectively. Paranasal sinuses and some tumours of the head and neck area, especially extended tumours with large fixed lymph nodes, are also indications for neutrons. By contrast, the results obtained for brain tumours were, in general, disappointing. Neutrons were shown to bring a benefit in the treatment of well differentiated slowly growing soft tissue sarcomas. The reported overall local control rates are 53 % and 38 % after neutron and photon irradiation respectively. Better results, after neutron irradiation, were also reported for bone- and chondrosarcomas. The reported local control rates are 54 % for osteosarcomas and 49 % for chondrosarcomas after neutron irradiation; the corresponding values are 21 % and 33 % respectively after photon irradiation. For locally extended prostatic adenocarcinoma, the superiority of mixed schedule (neutrons + photons) was demonstrated by a RTOG randomized trial (local control rates 77% for mixed schedule compared to 31 % for photons). Neutrons were also shown to be useful for palliative treatment of melanomas. Further studies are needed in order to definitively evaluate the benefit of fast neutrons for other localisations such as uterine cervix, bladder, and rectum.
    [Show full text]
  • Efficacy and Toxicity of Particle Radiotherapy in WHO Grade II and Grade III Meningiomas: a Systematic Review
    NEUROSURGICAL FOCUS Neurosurg Focus 46 (6):E12, 2019 Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review *Adela Wu, MD,1 Michael C. Jin, BS,2 Antonio Meola, MD, PhD,1 Hong-nei Wong, MLIS, DVM,3 and Steven D. Chang, MD1 1Department of Neurosurgery, Stanford Health Care, Palo Alto; 2Stanford University School of Medicine, Stanford; and 3Lane Medical Library, Stanford Medicine, Palo Alto, California OBJECTIVE Adjuvant radiotherapy has become a common addition to the management of high-grade meningiomas, as immediate treatment with radiation following resection has been associated with significantly improved outcomes. Recent investigations into particle therapy have expanded into the management of high-risk meningiomas. Here, the authors systematically review studies on the efficacy and utility of particle-based radiotherapy in the management of high-grade meningioma. METHODS A literature search was developed by first defining the population, intervention, comparison, outcomes, and study design (PICOS). A search strategy was designed for each of three electronic databases: PubMed, Embase, and Scopus. Data extraction was conducted in accordance with the PRISMA guidelines. Outcomes of interest included local disease control, overall survival, and toxicity, which were compared with historical data on photon-based therapies. RESULTS Eleven retrospective studies including 240 patients with atypical (WHO grade II) and anaplastic (WHO grade III) meningioma undergoing particle radiation therapy were identified. Five of the 11 studies included in this systematic review focused specifically on WHO grade II and III meningiomas; the others also included WHO grade I meningioma. Across all of the studies, the median follow-up ranged from 6 to 145 months.
    [Show full text]
  • Radiation Therapy in Adult Soft Tissue Sarcoma—Current Knowledge and Future Directions: a Review and Expert Opinion
    cancers Review Radiation Therapy in Adult Soft Tissue Sarcoma—Current Knowledge and Future Directions: A Review and Expert Opinion Falk Roeder Department of Radiotherapy and Radiation Oncology, Paracelsus Medical University, Landeskrankenhaus, Salzburg 5020, Austria; [email protected]; Tel.: +43-57-255-58923 Received: 1 October 2020; Accepted: 29 October 2020; Published: 3 November 2020 Simple Summary: Radiation therapy (RT) is an integral part of the treatment of adult soft-tissue sarcomas (STS). Although mainly used as perioperative therapy to increase local control in resectable STS with high risk features, it also plays an increasing role in the treatment of non-resectable primary tumors, oligometastatic situations, or for palliation. This review summarizes the current evidence for RT in adult STS including typical indications, outcomes, side effects, dose and fractionation regimens, and target volume definitions based on tumor localization and risk factors. It covers the different overall treatment approaches including RT either as part of a multimodal treatment strategy or as a sole treatment and is accompanied by a summary on ongoing clinical research pointing at future directions of RT in STS. Abstract: Radiation therapy (RT) is an integral part of the treatment of adult soft-tissue sarcomas (STS). Although mainly used as perioperative therapy to increase local control in resectable STS with high risk features, it also plays an increasing role in the treatment of non-resectable primary tumors, oligometastatic situations, or for palliation. Modern radiation techniques, like intensity-modulated, image-guided, or stereotactic body RT, as well as special applications like intraoperative RT, brachytherapy, or particle therapy, have widened the therapeutic window allowing either dose escalation with improved efficacy or reduction of side effects with improved functional outcome.
    [Show full text]
  • Toward Intensity Modulated Treatment on the University of Washington Clinical Neutron Therapy System
    AAMD 43rd Annual Meeting June 17 – 21, 2018 Toward Intensity Modulated Treatment on the University of Washington Clinical Neutron Therapy System Landon Wootton June 20th, 2018 AAMD 43rd Annual Meeting Austin, Texas Disclosures . This presentation does not constitute an endorsement of any product (for your neutron planning needs or otherwise). No funding sources or conflicts of interest to disclose. 1 AAMD 43rd Annual Meeting June 17 – 21, 2018 Learner Outcomes . Familiarity with the historical use and current indications for treatment with neutron therapy. Understand the design and function of the University of Washington Clinical Neutron Therapy System (CNTS). Awareness of different beam modeling approaches for the CNTS neutron beam. CNTS History at University of Washington • 1973-1984 – Laboratory based neutron beam – 22 MeV deuterons incident on a beryllium target – Fixed horizontal beam – Magnetic rectangular collimation – No wedges – Resulting beam depth dose characteristics similar to Co-60 – 604 Patient Treated 2 AAMD 43rd Annual Meeting June 17 – 21, 2018 CNTS History at University of Washington . 1979 – Installation of dedicated hospital based neutron treatment system begins as part of NIH grant. – Gantry with full range of rotational motion, collimator and built in wedges, flattening filter, MLCs. 1984 – October 19th: first patient treatment – >3000 patients treated since Radiation Biology • Neutrons are indirectly ionizing, and damage DNA through the secondary particles they produce. – Mostly low-energy, high-LET protons as well as some heavier ions. – Compare to photons/protons which primarily generate electrons. • This affords neutrons unique radiobiological advantages. – Can overcome radiation resistance of hypoxic cells. – Dense ionization results in more fatal cellular damage per dose.
    [Show full text]
  • Particle Therapy an Advanced Form of Radiation Treatment for Cancer
    Particle Therapy An advanced form of radiation Proposed integrated treatment for national network Proton Carbon/Proton cancer facility facility Particle therapy is similar to traditional forms of In other countries, particle therapy is recommended radiation therapy, but it offers an even more for some patients with difficult-to-treat cancers. targeted approach. This means that the risk of harm to tissue around a tumour is lower than Proton therapy has been approved overseas for use with standard radiation. Instead of x-rays used in in children, adolescents and young adults, who are standard radiation, particle therapy uses protons or more at risk of long-term side effects from heavy ions such as carbon, which have an improved traditional treatment approaches. ability to kill cancer cells. Particle therapy, like It minimises the radiation to critical standard radiation, is painless and delivers radiation structures in the body and limits the through the skin. And the particles release their risks of long-term side effects. energy at the site of the tumour more precisely. This makes the treatment suitable for cancers near critical parts of the body, such as the eyes, brain and spinal cord. As well as being very precise, carbon ions deposit more energy to the tumour than protons or standard radiation. This means carbon ion therapy can be more effective at killing tumours that are resistant to standard radiation. While traditional radiation therapy can target such tumours, there is a higher risk of side effects because of potential damage to the surrounding tissue and organs. More than 4500 Australian from particle therapy.
    [Show full text]
  • Position Paper on Particle Therapy
    POSITION PAPER ON PARTICLE THERAPY FACULTY OF RADIATION ONCOLOGY THE ROYAL AUSTRALIAN AND NEW ZEALAND COLLEGE OF RADIOLOGISTS® Name of document and version: Faculty of Radiation Oncology Position Paper on Particle Therapy Approved by: Faculty of Radiation Oncology Council Date of approval: 23 October 2015 ABN 37 000 029 863 Copyright for this publication rests with The Royal Australian and New Zealand College of Radiologists® The Royal Australian and New Zealand College of Radiologists Level 9, 51 Druitt Street Sydney NSW 2000 Australia Email: [email protected] Website: www.ranzcr.edu.au Telephone: +61 2 9268 9777 Facsimile: +61 2 9268 9799 Disclaimer: The information provided in this document is of a general nature only and is not intended as a substitute for medical or legal advice. It is designed to support, not replace, the relationship that exists between a patient and his/her doctor. CONTENTS Objectives .............................................................................................................. 3 Method .................................................................................................................... 3 About Radiation Oncology ................................................................................... 3 About Proton and Particle Therapy .................................................................... 4 Faculty of Radiation Oncology Position ............................................................. 6 The International Context ....................................................................................
    [Show full text]